Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Cabozantinib Approved in Japan for Advanced Hepatocellular Carcinoma

November 30th 2020

The Japanese Ministry of Health, Labor, and Welfare has approved cabozantinib for the treatment of patients with unresectable hepatocellular carcinoma that has progressed on prior systemic therapy.

FDA Grants Zanidatamab Breakthrough Status in HER2+ Biliary Tract Cancer

November 30th 2020

November 30, 2020 - The FDA has granted a breakthrough therapy designation to zanidatamab for the treatment of patients with HER2 gene–amplified biliary tract cancer who have received prior therapy.

Laparoscopic Gastrectomy Is Noninferior to Open Approach in Locally Advanced Gastric Cancer

November 29th 2020

Laparoscopic distal gastrectomy with D2 lymphadenectomy demonstrated comparable rates of 3-year relapse-free survival vs open distal gastrectomy in patients with locally advanced gastric cancer.

Dr. Kim on Curative Treatment Options in HCC

November 25th 2020

Joseph Kim, MD, discusses curative therapeutic options in hepatocellular carcinoma.

Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC

November 25th 2020

Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.

Nivolumab Approved in Europe for Advanced Esophageal Cancer

November 24th 2020

November 24, 2020 - The European Commission has approved nivolumab for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma following prior fluoropyrimidine- and platinum-based combination chemotherapy.

Dr. Janjigian on the Importance of First-Line Therapy Selection in Gastric Cancer

November 24th 2020

Yelena Y. Janjigian, MD, discusses the importance of selecting an optimal first-line therapy in gastric cancer.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Dr. Price on the Challenges of the CodeBreaK 100 Trial in GI Cancers

November 23rd 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses challenges faced during the CodeBreaK 100 trial in gastrointestinal cancers.

Role of HER2-Directed Therapies Rapidly Evolves in Esophageal and Gastric Cancer

November 23rd 2020

November 23, 2020 - Yelena Y. Janjigian, MD, discusses future research efforts are focused on examining anti–PD-1 combination strategies, particularly with HER2-directed therapies.

Sotorasib Displays Disease Control, Safety in KRAS G12C–Mutant Gastrointestinal Cancers

November 22nd 2020

Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.

Dr. Price on the Safety, Efficacy of AMG 510 in Advanced Gastrointestinal Cancers

November 21st 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

Sintilimab/Bevacizumab Biosimilar Combo Shows Superior OS, PFS Over Sorafenib in Advanced Unresectable HCC

November 21st 2020

November 21, 2020 - Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a significant improvement in overall survival and progression-free survival per Independent Radiographic Review Committee versus sorafenib in patients with advanced unresectable hepatocellular carcinoma.

Dr. Eng on Contraindications for Oxaliplatin-Based Therapy in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses contraindications for oxaliplatin-based therapy in colorectal cancer.

Dr. Bekaii-Saab on Improved Sequencing Strategies in HCC

November 19th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.

Dr. Janjigian on the Importance of Biomarker Testing in GI Cancers

November 19th 2020

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Ruesch Center Symposium to Spotlight Advances, Applications in GI Cancers, Luminary Awards

November 17th 2020

November 17, 2020 — The 11th Annual Ruesch Center Symposium, taking place virtually on November 20 to 21, 2020, will feature sessions that span innovations in gastrointestinal cancer, advances in nuclear imaging and therapy for neuroendocrine tumors, precision oncology web educational resource, and patient symposia, bringing participants together in a forum for discussion, networking, and debate on pressing issues in the field.

Dr. Brar on the Rise of New Treatment Approaches in HCC

November 16th 2020

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.

Sun Spotlights Advances Made in Advanced/Metastatic Gastric and GEJ Adenocarcinoma

November 16th 2020

Weijing Sun, MD, FACP, discusses the great need for effective first-line treatment options in advanced/metastatic gastric and GEJ adenocarcinoma.

Dr. Patel on Limitations With Chemotherapy in Pancreatic Cancer

November 14th 2020

Reema A. Patel, MD, discusses limitations with chemotherapy in pancreatic cancer.